Experts on watch for resistance to new flu drug
Japanese researchers yesterday described two H3N2 flu viruses with mutations that may increase resistance to the new flu antiviral baloxavir marboxil (Xofluza), approved by the US Food and Drug Administration (FDA) in October, a development they say bears watching.
Source: CIDRAP
Healthy Patients